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C-Reactive Protein as a Clinical Marker of Risk
To the Editor:
We read with great interest the article by Lagrand et al1 in
which the authors both review the role of C-reactive protein
(CRP) as a marker of cardiovascular risk and propose a pathoge-
netic role for CRP. Although the evidence reviewed by Lagrand
et al1 convincingly suggests an association between CRP and
cardiovascular risk, we are concerned that the authors appear to
assume that CRP is an established, independent risk factor and
that its measurement has defined clinical applications.
Although it has been shown in large epidemiological studies
that high concentrations of CRP are associated with increased
cardiovascular risk in both patients with coronary artery disease
and apparently healthy individuals, extrapolation of findings in
large epidemiological studies to the clinical setting may not be
straightforward. One of the difficulties for the application of
“epidemiological” results to the individual patient relates to the
lack of well-established CRP levels that can be considered to
represent accurate cutoff points to identify the individual patient
at risk. Different studies have used different analytical assays, and
therefore CRP levels vary significantly among these studies. For
example, mean CRP levels in apparently healthy men who
developed cardiovascular events were reported in one study to be
1.40 mg/L,2 whereas another study3 in patients with unstable
angina considered a value of 15.5 mg/L to represent the cutoff
level between low and high risk. Another difficulty is that despite
suggestions of stable CRP levels over time within individuals,
there are reports indicating that the intraindividual variability of
CRP may be high (between 42% and 63%).4 This finding of high
intraindividual variability in CRP levels is important in view of
the fact that in the large epidemiological studies, CRP concen-
trations differed only slightly, albeit significantly, between indi-
viduals with increased risk of cardiovascular events and those
with low risk. The issue of intraindividual CRP variability
requires further investigation in large studies. If the large vari-
ability is confirmed, strategies for the use of CRP as a prognostic
marker in the individual patient should be planned carefully.
Despite the convincing evidence of a relationship between CRP
concentrations and cardiovascular risk in large studies, CRP, as
well as other acute-phase reactants, is a nonspecific marker of
inflammation. A recent meta-analysis5 has shown that fibrinogen,
CRP, albumin (inverse relation), and leukocyte count were all
strongly related to cardiovascular risk. These observations5 sug-
gest that these markers may be closely interrelated and represent
only a nonspecific indication of inflammation and/or other
mechanisms underlying the atherogenic process.
Lagrand et al1 propose a most interesting pathogenetic hypoth-
esis involving CRP in atherogenesis and rapid coronary artery
disease progression. Their suggestion that CRP may have a causal
role is intriguing and clearly deserves further investigation in
well-designed studies. Undoubtedly, a better understanding of the
pathogenic role of CRP in ischemic heart disease may help to
speed up the process leading to the successful use of CRP as a
clinical marker of risk. At present, however, the use of CRP as a
prognostic marker in the individual patient (or the apparently
healthy subject) has limitations.
Professor J.C. Kaski
Dr. Xavier Garcia-Moll
Coronary Artery Disease Research Unit
St. George’s Hospital Medical School
London, UK
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Drs Kaski and Garcia-Moll address several important problems
with respect to C-reactive protein (CRP) as a cardiovascular risk
factor. First, they address the issue that owing to suboptimal
performance of the assays, CRP levels within the normal range
cannot be measured accurately enough to be useful in clinical
practice. This is to some extent indeed true. In clinical practice,
CRP is most often assessed to evaluate whether it is increased, eg,
to monitor the response to (antibiotic) therapy. The assay methods
used in clinical practice, eg, nephelometry, are able to accurately
determine increased levels of CRP but have never been optimized
to measure levels within the normal range. However, the recent
interest in measuring CRP levels within this range will undoubt-
edly stimulate improvement of the assay methods. Our own
experience is that normal CRP levels can be assessed by ELISA
with adequate reproducibility (the variation coefficient for levels
of 0.1 to 5 mg/L is 9% to 16%). Using this assay, we determined
CRP levels weekly in 20 healthy laboratory workers and found
that these levels may vary significantly in some persons. In-
creases in CRP levels were often associated with the occurrence
of minor clinical symptoms such as cough or backache; eg,
individuals with normal levels of about 1.5 mg/L may have
increases up to 10 mg/L during intercurrent (sub)clinical disease.
These slight increases of CRP were found to persist for days to
weeks. Hence, a single determination of CRP may not yield
reliable information about baseline levels, even when a reproduc-
ible assay is used. These observations, furthermore, emphasize
the second point raised by Drs Kaski and Garcia-Moll: the
intravariability (and intervariability) of CRP levels is high, as
confirmed by more recent studies.1 Possibly, repeated determina-
tions (for example, 3 times at monthly intervals) might provide a
better estimation of baseline levels.
Finally, the authors state that up to now CRP is not an
established independent risk factor for cardiovascular diseases.
When corrected for established cardiovascular risk factors, CRP
levels still add to the prediction of adverse cardiovascular events
or a worse outcome in healthy individuals, as well as in patients
with manifest cardiovascular disease. Whether CRP is unique
among the acute-phase proteins as a cardiovascular risk factor
cannot be definitely answered at the moment. In our article, we
wanted to pay attention to the fully ignored properties of CRP
described in 1974 by Kaplan et al,2 ie, that CRP is able to activate
complement via the classic pathway after binding to a suitable
ligand and hence may enhance inflammation. A proinflammatory
role of CRP, in our opinion, could very well explain the observed
associations with cardiovascular disease. In addition to the
arguments described in detail in our article, such as the localiza-
tion of CRP together with activated complement in atheroscle-
rotic vessels3 and infarcted myocardium,4 we have recently found
increased levels of CRP-complement complexes in infarcted
tissues from patients dying of acute myocardial infarction (AMI)
and in plasma of patients with AMI (manuscripts in preparation).
Because these complexes are specific markers for CRP-mediated
complement activation in vivo, these observations support such a
proinflammatory role of CRP in (human) AMI.
Intervention studies should reveal whether our hypothesis is
correct, ie, that the link between CRP and cardiovascular disease
is based on its proinflammatory role, as described in our article.
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